ANDA Postapproval Changes: Best Practices and Strategies to Avoid Common Quality Assessment Issues

  Рет қаралды 4,687

U.S. Food and Drug Administration

U.S. Food and Drug Administration

3 жыл бұрын

Niles Ron, PhD, MBA, Branch Chief for the Division of Post-Marketing Activities II, discusses common post-marketing quality assessment issues, strategies to avoid them, and best practices.
Learn more at: www.fda.gov/drugs/news-events...
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training - www.fda.gov/cdersbia
SBIA Listserv - public.govdelivery.com/accoun...
SBIA 2021 Playlist - • 2021 CDER Small Busine...
SBIA LinkedIn: / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cdersbialearn
Twitter - / fda_drug_info
Email - CDERSBIA@fda.hhs.gov  
Phone - (301) 796-6707 I (866) 405-5367

Пікірлер
Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020
28:11
ОБЯЗАТЕЛЬНО СОВЕРШАЙТЕ ДОБРО!❤❤❤
00:45
Spot The Fake Animal For $10,000
00:40
MrBeast
Рет қаралды 189 МЛН
50 YouTubers Fight For $1,000,000
41:27
MrBeast
Рет қаралды 212 МЛН
Administrative Aspects of Managing a Drug Master File (DMF)
23:56
U.S. Food and Drug Administration
Рет қаралды 3,3 М.
Introduction to “The ANDA Review Pathway” (11/28) Generic Drugs Forum 2017
9:26
U.S. Food and Drug Administration
Рет қаралды 3,1 М.
Non-clinical Evaluation of Immunogenicity Risk of Generic Complex Peptide Products
20:06
U.S. Food and Drug Administration
Рет қаралды 2,3 М.
Division of Filing Review: Helpful Tips for Submission of an ANDA or Controlled Correspondence
23:35
Introduction to the Drug Master File (DMF) Review Process
24:28
U.S. Food and Drug Administration
Рет қаралды 9 М.
Lifecycle Changes to Chemistry, Manufacture, and Controls in NDAs - REdI 2020
34:37
U.S. Food and Drug Administration
Рет қаралды 3,5 М.
Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA
1:56:59
U.S. Food and Drug Administration
Рет қаралды 9 М.
FDA Drug Info Rounds, July 2012: Patents and Exclusivity
3:20
U.S. Food and Drug Administration
Рет қаралды 17 М.
Module 6 - Applying MIDD Strategies to Decision-Making
1:29:45
U.S. Food and Drug Administration
Рет қаралды 165
Chemistry and Manufacturing Requirements for Early Clinical Development: What’s in there? Prove it.
1:02:19
ОБЯЗАТЕЛЬНО СОВЕРШАЙТЕ ДОБРО!❤❤❤
00:45